Company Profile - Merrimack Pharmaceuticals Inc
Introduction
Merrimack Pharmaceuticals Inc (Merrimack) is a clinical-stage biopharmaceutical company that develops and commercializes novel targeted solutions for the treatment of various types of cancers through its understanding of biological markers and cancer pathways. It's first commercial product was Onivyde (irinotecan liposome injection) a liposomal formulation for treating advanced pancreatic cancer patients. Merrimack is entitled to receive milestone payments related to sale of Onivyde and MM-436 to Ipsen SA. Merrimack is headquartered in Cambridge, Massachusetts, the US.
Company info
| Country (HQ): | United States |
| Sector: | Pharmaceuticals and Healthcare |
| Market Cap (US$ m): | 183 |
| Revenue (US$ m): |
Innovation ranking
Innovation score
Closest peers in the Pharmaceuticals and Healthcare sector
Innovation Ranking
Johnson & Johnson
United States
Pharmaceuticals and Healthcare
F. Hoffmann-La Roche Ltd
Switzerland
Pharmaceuticals and Healthcare
Merrimack Pharmaceuticals Inc
United States
Pharmaceuticals and Healthcare
EyeGate Pharmaceuticals Inc
United States
Pharmaceuticals and Healthcare
Shin Poong Pharm Co Ltd
South Korea
Pharmaceuticals and Healthcare
Are you ranked? Get the Innovation Ranking Report
-
Company Ranking Report
- If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
- Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
- Contextualised information on the company's standing in relation to peers
- Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
- Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
- Rosettes
- Certificate of Achievement
- Press release
